ADBE
Adobe Inc.
ADBE has the edge over UNH overall, supported by stronger valuation and stronger fundamentals.
UNH
UnitedHealth Group Incorporated
UNH's outlook is improving, though it still trails on the overall score.
ADBE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ADBE's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ADBE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.9x | $239 | — |
| Current | 13x | $239 | — |
| Cheap | 22x | $396 | +66% |
| Fair | 43x | $771 | +223% |
| Expensive | 54x | $972 | +308% |
Historical ranges are pointers, not guarantees.
ADBE has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ADBE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
ADBE has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ADBE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.84 | +50% |
| Q3 2026 | $17.91 | +12% |
| Q2 2026 | $17.47 | +12% |
| Q1 2026 | $17.16 | +13% |
| Q4 2025 | $16.70 | +35% |
| Q3 2025 | $16.01 | +35% |
| Q2 2025 | $15.59 | +40% |
| Q1 2025 | $15.14 | +45% |
| Q4 2024 | $12.36 | +4.6% |
ADBE has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ADBE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.8B | +13% |
| Q2 2026 | $6.6B | +13% |
| Q1 2026 | $6.4B | +12% |
| Q4 2025 | $6.2B | +10% |
| Q3 2025 | $6B | +11% |
| Q2 2025 | $5.9B | +11% |
| Q1 2025 | $5.7B | +10% |
| Q4 2024 | $5.6B | +11% |
ADBE has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | -1.5 points |
| Q2 2026 | 34% | -2.1 points |
| Q1 2026 | 38% | -0.1 points |
| Q4 2025 | 37% | +1.6 points |
| Q3 2025 | 36% | -0.5 points |
| Q2 2025 | 36% | +0.4 points |
| Q1 2025 | 38% | +20 points |
| Q4 2024 | 35% | +0.4 points |
ADBE has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ADBE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.4B | +15% |
| Q2 2026 | $2.1B | -1.7% |
| Q1 2026 | $2.9B | +19% |
| Q4 2025 | $3.1B | +8.8% |
| Q3 2025 | $2.1B | +8.2% |
| Q2 2025 | $2.1B | +13% |
| Q1 2025 | $2.5B | +116% |
| Q4 2024 | $2.9B | +85% |
ADBE has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ADBE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
ADBE has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ADBE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 25.8 | Neutral |
ADBE's weekly RSI is 45 (neutral) and its Stochastic is 26 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ADBE PE vs Technology Sector
| Metric | ADBE | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 28x | 52% below |
| PE % | 3 | 35 | 32 pts below |
ADBE has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ADBE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $244.1 | 2.3% below |
| 20 week MA | $248.6 | 4.1% below |
| 50 week MA | $261.6 | 8.8% below |
| 100 week MA | $321.8 | 26% below |
| 200 week MA | $410.6 | 42% below |
ADBE is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ADBE on trend strength, trading above more of its moving averages.
ADBE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.8 | $499.9 | +51% |
| 2021 | $499.9 | $569.6 | +14% |
| 2022 | $569.6 | $338.5 | -41% |
| 2023 | $338.5 | $596.6 | +76% |
| 2024 | $596.6 | $446.5 | -25% |
| 2025 | $446.5 | $353.8 | -21% |
| 2026 YTD | $353.8 | $238.5 | -33% |
ADBE has finished lower in three of the last six years. It's down 33% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ADBE on returns for 2026, with the stronger performance.